Word: moneymen
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...movie will likely score big at the box office, and that might make Hollywood moneymen less dismissive of thoughtful Africa-focused films. But will Hotel Rwanda redirect America’s attention to the humanitarian crises of our day? Rusesabagina thinks so. “Whenever people are informed, that has an impact,” he says. George adds that he “felt good about the notion that we would at least stimulate people to get involved and mobilize...
Wall Street moneymen have been among the most aggressive in raising dividends: Goldman Sachs, where executives and directors collectively own 25 million company shares, doubled its annual payout to $1 a share. After tax, CEO Henry Paulson's 4 million shares will spin off $3.4 million in dividends--up from $1.2 million. Goldman spokesman Peter Rose says it's "preposterous" that the move had anything to do with personal enrichment and that Goldman's dividend was merely brought up to the industry average. Bear Stearns, long famous for nosebleed executive pay, raised its dividend 18%, to 80 a share. After...
...Independent Film Channel's three-part documentary A Decade Under the Influence (Aug. 20-22, 8 p.m. E.T.) sees the 1970s in movies as an interregnum between the old studio system and today's blockbuster machine, when idiosyncratic directors were able to persuade the moneymen to bankroll dark, even cynical, movies like MASH and Network for a mass audience. It's a familiar thesis--see Peter Biskind's 1998 book Easy Riders, Raging Bulls--but well fleshed out with interviews with big names (Scorsese, Coppola, Altman) who rise to the always daunting challenge of explaining why their work...
...deliver wonder drugs that will cure feared ailments like cancer and Alzheimer's; compared to that, budgetary discipline seems pretty dull. Yet with an exhaustingly long list of failed products and failed companies in its brief past, the biotech industry each year grows closer to losing sway with the moneymen who fund its research. Even though biotech stocks have been moving up this year, among critical pre-ipo investors like venture-capital funds "there's a lot of fear," says Alan Crane, ceo of Momenta Pharmaceuticals, an early-stage drug-discovery firm. "There's a lot of concern about losing...
...years ago has been its promise to deliver wonder drugs that will cure feared ailments like cancer and Alzheimer's. Yet with an exhaustingly long list of failed products and failed companies in its brief past, the industry each year grows closer to losing sway with the moneymen who fund its research. Even though biotech stocks have been moving up this year, among critical pre-IPO investors like venture-capital funds "there's a lot of fear," says Alan Crane, CEO of Momenta Pharmaceuticals, an early-stage drug-discovery firm. "There's a lot of concern about losing your money...